RxSight Light Adjustable Lens and Light Delivery Device New Enrollment Study

NACompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

December 3, 2021

Primary Completion Date

September 11, 2024

Study Completion Date

December 16, 2024

Conditions
AphakiaCataract
Interventions
DEVICE

Light Adjustable lens (LAL) and Light Delivery Device (LDD)

Experimental treatment group will receive Light adjustable lens with Light delivery Device treatments

DEVICE

Control IOL

Control treatment group will receive a Control IOL

Trial Locations (14)

29464

Carolina Eyecare Physicians, LLC, Mt. Pleasant

33770

The Eye Institute of West Florida, Largo

33870

Newsom Eye, Sebring

44141

Cleveland Eye Clinic, Brecksville

56308

Vance Thompson Vision, Alexandria

57108

Vance Thompson Vision Clinic, Sioux Falls

68137

Vance Thompson Vision, Omaha

72704

Vold Vision, Fayetteville

75235

Key-Whitman Eye Center, Dallas

76054

Texas Eye Research Center, Hurst

77027

Slade & Baker Vision, Houston

78229

Focal Point Vision, San Antonio

89145

Center for Sight, Las Vegas

95926

Reeve Woods Eye Center, Chico

All Listed Sponsors
lead

RxSight, Inc.

INDUSTRY

NCT05202808 - RxSight Light Adjustable Lens and Light Delivery Device New Enrollment Study | Biotech Hunter | Biotech Hunter